Pacer Advisors
SRPT icon

Pacer Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Pacer Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
+2,065
New +$39.1K ﹤0.01% 2109
2025
Q2 		– Sell
-6,999
Closed -$447K – 3586
2025
Q1 		$447K Sell
6,999
-13,056
-65% -$1.37M ﹤0.01% 1505
2024
Q4 		$2.44M Sell
20,055
-932
-4% -$114K 0.01% 893
2024
Q3 		$2.62M Buy
20,987
+5,989
+40% +$828K 0.01% 850
2024
Q2 		$2.37M Buy
14,998
+14,654
+4,260% +$1.88M 0.01% 843
2024
Q1 		$44.5K Buy
+344
New +$42.1K ﹤0.01% 3214
2021
Q2 		– Sell
-895
Closed -$67K – 1545
2021
Q1 		$67K Buy
895
+66
+8% +$6.09K ﹤0.01% 1393
2020
Q4 		$141K Buy
829
+168
+25% +$24.9K ﹤0.01% 1292
2020
Q3 		$93K Buy
+661
New +$100K ﹤0.01% 1259
2018
Q4 		– Sell
-2,580
Closed -$417K – 973
2018
Q3 		$417K Buy
+2,580
New +$353K 0.02% 900
2018
Q1 		– Sell
-2,600
Closed -$145K – 1123
2017
Q4 		$145K Buy
+2,600
New +$138K 0.01% 927

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pacer Advisors's SRPT Position: Q2 2026 in Review

Pacer Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 2,065 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2109 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in SRPT as recently as Q1 2025.

Pacer Advisors first reported a position in SRPT in Q4 2017 and has held it in 11 quarters since. The position peaked at $2.62M in Q3 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Pacer Advisors held 2,065 shares of Sarepta Therapeutics worth $37K as of Q2 2026.
  • Sarepta Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2109 holding.
  • Pacer Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 11 quarters since.
  • Pacer Advisors's Sarepta Therapeutics position peaked at $2.62M in Q3 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.